Skip to main content

Advertisement

Log in

The Role of Growth Differentiation Factor-9 (GDF-9) and Its Analog, GDF-9b/BMP-15, in Human Breast Cancer

  • Laboratory Research
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

There has been a recent surge of interest in the role of growth differentiation factors and other bone morphogenic proteins in the development and spread of cancer. In this study we have provided evidence that highlights the significance of growth and differentiation factor-9a (GDF-9a) and GDF-9b (bone morphogenic protein-15, BMP-15) in breast cancer development and progression.

Methods

Primary breast cancer samples (n = 109) and matched background tissues from same patients (n = 33) were processed for frozen section and RNA extraction. Frozen sections from matched tissues were immunostained with GDF-9a and GDF-9b antibodies. Staining intensity was analyzed by computer image analysis. RNA was reverse transcribed and quantified before analysis by quantitative polymerase chain reaction (Q-PCR). Results were expressed as number of transcripts (standardized by β-actin). The data were compared with the clinical outcome of the disease. The biological effects of the molecule were studied using in vitro assays after forced expression in breast cancer cells.

Results

Highly aggressive breast cancer cells did not express GDF-9a. On forced expression of GDF-9a, breast cancer cells became less invasive. These laboratory findings were analyzed against the clinical information. Primary breast cancer samples with good predicted prognosis had a significantly higher level of GDF-9a than in samples with poor predicted prognosis (P = .004). Patients who remained disease-free at the end of a 10-year follow-up had significantly higher levels of both GDF-9a and GDF-9b in their tissue than those with poor clinical outcome (P = .001 and .014, respectively).

Conclusion

Growth differentiation factor-9 family expressed in breast cancer has an inhibitory effect on the progression of human breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

FIG. 1.
FIG. 2.
FIG. 3.
FIG. 4.
FIG. 5.
FIG. 6.
FIG. 7.

Similar content being viewed by others

References

  1. Pisani P, Parkin DM, Ferlay J. Estimates of worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891–903

    Article  PubMed  CAS  Google Scholar 

  2. Urist MR. Bone formation by autoregulation. Science 1965; 150:893–9

    Article  PubMed  CAS  Google Scholar 

  3. Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol 1998; 12:1809–17

    Article  PubMed  CAS  Google Scholar 

  4. Phippard DJ, Weber-Hall SJ, Sharpe PT, Naylor MS, Jayatalake H, Maas R, Woo I, Roberts-Clarke D, Francis-West PH, Liu YH, Maxson R, Hill RE, Dale TC. Regulation of MSX-1, MSX-2, BMP-2 and BMP-4during foetal and post-natal mammary gland development. Development 1996; 22:2729–37

    Google Scholar 

  5. Wang EA, Rosen V, D’Alessandro JS, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990; 87:2220–4

    Article  PubMed  CAS  Google Scholar 

  6. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB. Evidence of transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48:417–28

    Article  PubMed  CAS  Google Scholar 

  7. Clement JH, Sanger J, Hoffken K. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and regulation by epidermal growth factors. Int J Cancer 1999; 80(2):250–6

    Article  PubMed  CAS  Google Scholar 

  8. Schwalbe M, Sanger J, Eggers R, Nauman A, Schmidt A, Hoffken K, Clement JH. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol 2003; 23(1):89–95

    PubMed  CAS  Google Scholar 

  9. Arnold SF, Tims E, Mcgrath BE. Identification of bone morphogenetic proteins and their receptors in human breast cancer cells lines: importance of BMP2. Cytokine 1999: 11(12):1031–7

    Article  PubMed  CAS  Google Scholar 

  10. Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett. 1998; 127:29–35

    Article  PubMed  CAS  Google Scholar 

  11. Kang Y, Seigel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3(6):537–49

    Article  PubMed  CAS  Google Scholar 

  12. Hanavadi S, Martin TA, Mansel RE, Jiang WG. Interleukin-11 and its receptor expression in human breast cancer. Ann Surg Oncol 2006; 13(6):802–8

    Article  PubMed  Google Scholar 

  13. Hanavadi S, Martin TA, Mansel RE, Jiang WG. Bone morphogenic protein (BMP)-15 is reduced by Interleukin-11 in human breast cancer cells. Breast Cancer Res Treat 2004; 88(Suppl 1):S248

    Google Scholar 

  14. Incerti B, Dong J, Borsani G, Matzuk MM. Structure of the mouse growth differentiation factor 9 gene. Biochim Biophys Acta 1994; 1222:125–8

    Article  PubMed  CAS  Google Scholar 

  15. McGrath SA, Esquela AF, Lee SJ. Oocyte-specific expression of growth differentiation factor-9. Mol Endocrinol 1995; 9:131–6

    Article  PubMed  CAS  Google Scholar 

  16. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22(3):207–19

    Article  PubMed  CAS  Google Scholar 

  17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–10

    Article  PubMed  CAS  Google Scholar 

  18. Chomczynske P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156–159

    Google Scholar 

  19. Jiang WG, Watkins G, Lane J, Douglas-Jones A, Cunnick GH, Mokbel M, Mansel RE. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res 2003; 9(17):6432–40

    PubMed  CAS  Google Scholar 

  20. Davies G, Jiang WG, Mason MD. Cell–cell adhesion and signaling intermediates in human prostate cancer. J Urol 2000; 163:985–92

    Article  PubMed  CAS  Google Scholar 

  21. Aaltonen J, Laitinen MP, Vuojolainen K, et al. Human growth differentiation factor-9 (GDF-9) and its novel homolog GDF-9b are expressed in oocyte during early folliculogenesis. J Clin Endocrinol Metab 1999; 84:2744–50

    Article  PubMed  CAS  Google Scholar 

  22. Erickson GF, Shimasaki S. The role of oocyte in folliculogenesis. Trends Endocrinol Metab 2000; 11:193–8

    Article  PubMed  CAS  Google Scholar 

  23. Hayashi M, McGee EA, Min G, Klein C, Rose UM, van Duin M, Hsueh AJ. Recombinant growth differentiation factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles. Endocrinology 1999; 140:1236–44

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors wish to thank Cancer Research Wales (CRW) and Cancer Research UK (CR-UK) for supporting.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to W. G. Jiang MB BCh, MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanavadi, S., Martin, T.A., Watkins, G. et al. The Role of Growth Differentiation Factor-9 (GDF-9) and Its Analog, GDF-9b/BMP-15, in Human Breast Cancer. Ann Surg Oncol 14, 2159–2166 (2007). https://doi.org/10.1245/s10434-007-9397-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9397-5

Keywords

Navigation